NewsCiRA_F and CIRM Sign Agreement for Widespread Use of iPS Cell Stock

We, the CiRA Foundation, are pleased to announce our participation as an "Industry Resource Partner" in the Industry Alliance Program at the California Institute for Regenerative Medicine (CIRM).

CIRM is dedicated to promoting commercialization in the fields of stem cells, gene therapy, and regenerative medicine. In addition to grants from the California state government for various stages of research, the Industry Alliance Program provides CIRM grant recipients with industry resources needed for commercialization.

The agreement will enable the CiRA Foundation to efficiently deliver its iPS cell stock for regenerative medicine to universities, companies, and projects supported by CIRM, which follows our mandate for wide-spread use of our iPS cell stock as a raw material for regenerative medicine products.

About the California Institute for Regenerative Medicine (CIRM)

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the world's largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.
For more information go